Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
Ray KK, Troquay RPT, Visseren FLJ, et al.
Lancet Diabetes Endocrinol. 2023;S2213-8587(22)00353-9.
Leggi